CT colonography exams are difficult and time consuming to read and interpret, a potential barrier to more widespread colon cancer screening. Computer-aided detection has a potential role to play in that effort, according to a study presented at the
CT colonography exams are difficult and time consuming to read and interpret, a potential barrier to more widespread colon cancer screening. Computer-aided detection has a potential role to play in that effort, according to a study presented at the American Roentgen Ray Society meeting in May.
Dr. Abraham H. Dachman and colleagues at the University of Chicago retrospectively studied 20 CT colonography data sets: 10 sets consisted of 11 polyps, 5 to 12 mm in size, and 10 were normal. Four readers (two attending radiologists, a radiology resident, and a gastroenterologist) reviewed the data sets with and without computer-aided detection.
Readers missed 42% of the polyps without CAD; they later identified 75% of the missed polyps with the help of the CAD system. CAD detected all the polyps missed by the readers, while readers correctly dismissed 77% of the computer's false positives.
The average area under the ROC curve (Az values) for radiologists without and with CAD were 0.70 and 0.85, respectively. The difference was statistically significant. The increase in the Az value was the largest for the gastroenterologist (0.21) among the four observers.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.